Treatment and early outcome of 11 children with hepatoblastoma

Aim: This study was designed to retrospectively review our experience National Cancer Institute, Cairo University with the multimodality management of hepatoblastomas (HB) and to assess the outcome of childhood hepatoblastoma after a combination therapy of resection and chemotherapy. Materials and Methods: eleven patients were treated for HB between 2006 and 2010. The clinical presentations, chemotherapy tolerance and response and surgical procedure undertaken were analysed. Results: Median age of the population was 15 months (6-37 months), mean age was 16.7 months; with a male-to-female ratio of 4.5:1. Nine patients were treated with neoadjuvant chemotherapy incorporating cisplatin and adriamycin. Primary surgery was done in two patients. Extent of hepatic resection in the operated patients varied. Mixed type was the predominant histopathological diagnosis. Adjuvant chemotherapy was well tolerated with no morbidity or mortality. All the nine patients who could complete multimodality treatment are alive with no evidence of disease or complications with median follow-up of 13 months (7-19 months), mean follow up was 12.2 months. Overall Survival of all 11 patients is 91%. Conclusion: Treatment of HB with midtidisciplinary approach was well tolerated. Overall Survival of patients were comparable with published studies.